The Prevalence, Impact, and Treatment of Migraine and Severe Headaches in the U nited S tates: A Review of Statistics From National Surveillance Studies

Background Four ongoing US public health surveillance studies gather information relevant to the prevalence, impact, and treatment of headache and migraine: the N ational H ealth I nterview S urvey, the N ational H ealth and N utrition E xamination S urvey, the N ational A mbulatory C are S urvey, and the N ational H ospital A mbulatory M edical C are S urvey. The A merican M igraine P revalence and P revention ( AMPP ) study is a privately funded study that provides comparative US population‐based estimates of the prevalence and burden of migraine and chronic migraine. Objective To gather in one place and compare the most current available estimates of the US adult prevalence of headache and migraine, and the number of affected people overall and in various subgroups, and to provide estimates of headache burden and treatment patterns by examining migraine and headache as a reason for ambulatory care and emergency department ( ED ) visits in the U nited S tates. Methods We reviewed published analyses from available epidemiological studies identified through searches of PubMed and the N ational C enter for H ealth S tatistics. We aimed to identify information about migraine and headache burden, and treatment in national surveys conducted over the last decade. For each source, we selected the best available and most current estimate of migraine or headache prevalence, and selected associated measures of disability, health care use, and treatment patterns. Results Compared with a slightly higher proportion of 22.7% in the N ational H ealth and N utrition E xamination S urvey, 16.6% of adults 18 or older reported having migraine or other severe headaches in the last 3 months in the 2011 N ational H ealth I nterview S urvey. In contrast, the AMPP study found an overall prevalence of migraine of 11.7% and probable migraine of 4.5%, for a total of 16.2%. Data from N ational A mbulatory M edical C are S urvey/ N ational H ospital A mbulatory M edical C are S urvey showed that head pain was the fifth leading cause of ED visits overall in the US and accounted for 1.2% of outpatient visits. The burden of headache was highest in females 18‐44, where the 3‐month prevalence of migraine or severe headache was 26.1% and head pain was the third leading cause of ED visits. The prevalence and burden of headache was substantial even in the least affected subgroup of males 75 or older, where 4.6% reported experiencing severe headache or migraine in the previous 3 months. Triptans accounted for almost 80% of antimigraine analgesics prescribed at office visits in 2009, nearly half of which were for sumatriptan. Migraine is associated with increased risk for other physical and psychiatric comorbidities, and this risk increases with headache frequency. Conclusion This report provides the most current available estimates of the prevalence, impact, and treatment patterns of